Please try another search
For the three months ended 31 March 2020, Allergan plc revenues remained flat at $3.6B. Net income totaled $378M vs. loss of $2.41B. Revenues reflect US General Medicine segment increase of 5% to $1.31B, Other segment increase from $2.8M to $51M, also reflect International segment decrease of 13% to $690M, Nephrology segment decrease of 87% to $1.4M. Net income reflects Goodwill impairments decrease of 63% to $913M (expense).
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Total Revenue | 3604.4 | 4351 | 4050.7 | 4090.1 |
Gross Profit | 3008.1 | 3653.9 | 3411.9 | 3437.9 |
Operating Income | -1299.6 | -276.6 | -596.6 | -1262.8 |
Net Income | 378 | -317.2 | -786.8 | -1759 |
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Total Assets | 88426.2 | 94699.1 | 94408.9 | 95480.7 |
Total Liabilities | 30428.5 | 36525.5 | 35933.7 | 35806 |
Total Equity | 57997.7 | 58173.6 | 58475.2 | 59674.7 |
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | 116.5 | 7238.7 | 5568.4 | 2644.3 |
Cash From Investing Activities | 1679.1 | -2858.8 | -2632.7 | 462.6 |
Cash From Financing Activities | -3268.4 | -2766.1 | -2568.6 | -2338.6 |
Net Change in Cash | -1503.8 | 1622.9 | 357.1 | 771 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review